MYO9A-HEXA Fusion FISH Probe
The MYO9A-HEXA Fusion FISH Probe is used to confirm a fusion of the MYO9A and HEXA genes. The fusion of the MYO9A and HEXA genes has been associated with Breast Invasive Carcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.
** This product is for in vitro and research use only. This product is not intended for diagnostic use. Please note that both genes fall on the same chromosome and inter-chromosomal detection may be difficult to detect depending on the genes proximity to one another. Please consult our support staff before ordering this product to ensure that the probe can be designed to meet your specific needs.
| SKU | Test Kits | Buffer | Dye Color | Order Now |
|---|---|---|---|---|
| MYO9A-HEXA-20-ORGR (Standard Design) | 20 (40 μL) | 200 μL |
|
|
| MYO9A-HEXA-20-RERE | 20 (40 μL) | 200 μL |
|
|
| MYO9A-HEXA-20-REOR | 20 (40 μL) | 200 μL |
|
|
| MYO9A-HEXA-20-REGO | 20 (40 μL) | 200 μL |
|
|
| MYO9A-HEXA-20-REGR | 20 (40 μL) | 200 μL |
|
|
| MYO9A-HEXA-20-REAQ | 20 (40 μL) | 200 μL |
|
|
| MYO9A-HEXA-20-ORRE | 20 (40 μL) | 200 μL |
|
|
| MYO9A-HEXA-20-OROR | 20 (40 μL) | 200 μL |
|
|
| MYO9A-HEXA-20-ORGO | 20 (40 μL) | 200 μL |
|
|
| MYO9A-HEXA-20-ORAQ | 20 (40 μL) | 200 μL |
|
|
| MYO9A-HEXA-20-GORE | 20 (40 μL) | 200 μL |
|
|
| MYO9A-HEXA-20-GOOR | 20 (40 μL) | 200 μL |
|
|
| MYO9A-HEXA-20-GOGO | 20 (40 μL) | 200 μL |
|
|
| MYO9A-HEXA-20-GOGR | 20 (40 μL) | 200 μL |
|
|
| MYO9A-HEXA-20-GOAQ | 20 (40 μL) | 200 μL |
|
|
| MYO9A-HEXA-20-GRRE | 20 (40 μL) | 200 μL |
|
|
| MYO9A-HEXA-20-GROR | 20 (40 μL) | 200 μL |
|
|
| MYO9A-HEXA-20-GRGO | 20 (40 μL) | 200 μL |
|
|
| MYO9A-HEXA-20-GRGR | 20 (40 μL) | 200 μL |
|
|
| MYO9A-HEXA-20-GRAQ | 20 (40 μL) | 200 μL |
|
|
| MYO9A-HEXA-20-AQRE | 20 (40 μL) | 200 μL |
|
|
| MYO9A-HEXA-20-AQOR | 20 (40 μL) | 200 μL |
|
|
| MYO9A-HEXA-20-AQGO | 20 (40 μL) | 200 μL |
|
|
| MYO9A-HEXA-20-AQGR | 20 (40 μL) | 200 μL |
|
|
| MYO9A-HEXA-20-AQAQ | 20 (40 μL) | 200 μL |
|
HEXA Gene Summary
This gene encodes a member of the glycosyl hydrolase 20 family of proteins. The encoded preproprotein is proteolytically processed to generate the alpha subunit of the lysosomal enzyme beta-hexosaminidase. This enzyme, together with the cofactor GM2 activator protein, catalyzes the degradation of the ganglioside GM2, and other molecules containing terminal N-acetyl hexosamines. Mutations in this gene lead to an accumulation of GM2 ganglioside in neurons, the underlying cause of neurodegenerative disorders termed the GM2 gangliosidoses, including Tay-Sachs disease (GM2-gangliosidosis type I). Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed. [provided by RefSeq, Jan 2016]
Gene Name: Hexosaminidase Subunit Alpha
Chromosome: CHR15: 72635777 -72668520
Locus: 15q23
MYO9A Gene Summary
This gene encodes a member of the myosin superfamily. The protein represents an unconventional myosin; it should not be confused with the conventional non-muscle myosin-9 (MYH9). Unconventional myosins contain the basic domains of conventional myosins and are further distinguished from class members by their tail domains. They function as actin-based molecular motors. Mutations in this gene have been associated with Bardet-Biedl Syndrome. [provided by RefSeq, Dec 2011]
Gene Name: Myosin IXA
Chromosome: CHR15: 72118360 -72410422
Locus: 15q23
Gene Diseases
The MYO9A HEXA Fusion has been associated with the following diseases:
| Disease Name |
|---|
| Breast Invasive Carcinoma |
FISH Probe Protocols
| Protocol, Procedure, or Form Name | Last Modified | Download |
|---|